Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando E Membreno

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinics in Liver Disease|August 27, 2011
The HCV NS5B nucleoside and non-nucleoside inhibitorsFernando E Membreno, Eric J Lawitz
Journal of Gastroenterology and Hepatology|May 24, 2014
Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospectsEric J Lawitz, Fernando E Membreno
Gastroenterology Clinics of North America|August 25, 2004
Antiviral therapy for treatment-naïve hepatitis B virus patientsDaryl T-Y Lau, Fernando E Membreno
Clinics in Liver Disease|November 27, 2012
Cyclophilin inhibitors for hepatitis C therapyFernando E Membreno, Jennifer C Espinales, Eric J Lawitz
Gastrointestinal Endoscopy|April 1, 2003
PinwormsSohaib Faruqi, Ijaz Ahmed, Fernando E Membreno, et al.
Clinical Transplantation|April 24, 2008
Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive disease): case report with review of the literature and the UNOS databaseFernando E Membreno, Jorge Ortiz, Preston F Foster, et al.
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 26, 2025
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver DiseaseNaim Alkhouri, Parvez Mantry, Humberto C Gonzalez, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinics in Liver Disease|August 27, 2011
The HCV NS5B nucleoside and non-nucleoside inhibitorsFernando E Membreno, Eric J Lawitz
Journal of Gastroenterology and Hepatology|May 24, 2014
Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospectsEric J Lawitz, Fernando E Membreno
Gastroenterology Clinics of North America|August 25, 2004
Antiviral therapy for treatment-naïve hepatitis B virus patientsDaryl T-Y Lau, Fernando E Membreno
Clinics in Liver Disease|November 27, 2012
Cyclophilin inhibitors for hepatitis C therapyFernando E Membreno, Jennifer C Espinales, Eric J Lawitz
Gastrointestinal Endoscopy|April 1, 2003
PinwormsSohaib Faruqi, Ijaz Ahmed, Fernando E Membreno, et al.
Clinical Transplantation|April 24, 2008
Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive disease): case report with review of the literature and the UNOS databaseFernando E Membreno, Jorge Ortiz, Preston F Foster, et al.
Hepatology (Baltimore, Md.)|October 18, 2014
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosisEric Lawitz, Fred Poordad, Diana M Brainard, et al.
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 26, 2025
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver DiseaseNaim Alkhouri, Parvez Mantry, Humberto C Gonzalez, et al.
Pageof 1